Physician profile
Meyer Abittan
NPI 1548248339
$28,352.29
in general payments reported to CMS, 2019-2025
41 companies · $1,752 in 2025
The $1,752 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $1,630 · 2021: $2,062 · 2022: $1,816 · 2023: $1,911 · 2024: $1,880 · 2025: $1,752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,495 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27.89 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,495.48 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27.89 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $10,404.52 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $5,039.68 | 2019 | |
| Amgen INC. | $1,619.28 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $1,454.51 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $1,136.00 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $1,100.58 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $932.30 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Novartis Pharmaceuticals Corporation | $919.22 | 2019-2025 | |
| Abbott Laboratories | $755.81 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Merck Sharp & Dohme LLC | $737.84 | 2021-2025 | Verquvo, Capvaxive |
| Chiesi USA, INC. | $653.94 | 2019-2025 | Kengreal, Cleviprex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $626.28 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $540.39 | 2021-2025 | Nexletol, Nexlizet |
| Boston Scientific Corporation | $397.27 | 2019-2024 | Rotapro, Watchman Flx, Watchman Access System |
| Arbor Pharmaceuticals, INC. | $202.25 | 2019-2021 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $177.42 | 2025 | |
| Althera Pharmaceuticals LLC | $175.47 | 2022 | |
| Novo Nordisk INC | $152.21 | 2023-2025 | Ozempic, Rybelsus |
| Kowa Pharmaceuticals America, INC. | $148.24 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $103.11 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $102.52 | 2024 | Arcalyst |
| Lundbeck LLC | $95.61 | 2019-2020 | |
| Medicomp INC | $94.11 | 2022-2025 | Telepatch Cardiac Monitor |
| Lexicon Pharmaceuticals, INC. | $81.57 | 2023-2024 | Inpefa |
| Bridgebio Pharma, INC. | $81.43 | 2025 | Attruby |
| Kiniksa Pharmaceuticals, LTD. | $81.03 | 2023 | Arcalyst |
| Gilead Sciences, INC. | $68.92 | 2019 | |
| Irhythm Technologies, INC. | $55.75 | 2019-2023 | Zio Xt Patch |
| Bardy Diagnostics, INC. | $52.00 | 2020 | |
| Glaxosmithkline, LLC. | $51.99 | 2025 | Arexvy, Shingrix |
| Cvrx, INC. | $48.18 | 2025 | Barostim Neo System |
| Daiichi Sankyo INC. | $45.70 | 2019-2024 | Injectafer |
| Exact Sciences Corporation | $30.59 | 2025 | Cologuard Collection Kit |
| Medicure Pharma INC. | $27.89 | 2024 | Zypitamag |
| Alnylam Pharmaceuticals INC. | $26.78 | 2025 | Amvuttra |
| Cardiva Medical, INC. | $24.52 | 2025 | Cardiva Vascade 6/7f Vcs |
| Inspire Medical Systems, INC. | $23.85 | 2024 | Inspire |
| Xeris Pharmaceuticals, INC. | $23.64 | 2025 | Gvoke Hypopen |
| Baxter Healthcare | $23.52 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Heartflow, INC. | $19.14 | 2023 | Ffrct |
| Penumbra, INC. | $17.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meyer Abittan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.